Vancomycin AUC/MIC and Corresponding Troughs in a Pediatric Population

Insights

Vancomycin dosing in children for MRSA infections is challenging. A 15 mg/kg dose every 6 hours has a variable probability of achieving the target AUC/MIC > 400, correlating to a trough of 11 mg/L.

Area of Science:

  • Pediatric Infectious Diseases
  • Pharmacokinetics and Pharmacodynamics
  • Antimicrobial Stewardship

Background:

  • Adult guidelines recommend vancomycin AUC/MIC > 400 for MRSA, corresponding to trough concentrations of 15-20 mg/L.
  • Achieving target vancomycin troughs in pediatric patients is clinically challenging.
  • Pediatric vancomycin dosing requires specific pharmacokinetic evaluation.

Purpose of the Study:

  • To assess the likelihood of achieving an AUC/MIC > 400 with vancomycin 15 mg/kg every 6 hours in pediatric patients.
  • To determine the correlation between vancomycin trough concentrations and AUC/MIC targets in children.
  • To evaluate the impact of different pharmacokinetic methods on AUC/MIC calculations.

Main Methods:

  • Retrospective chart review of pediatric patients (>2 months to <18 years) with S. aureus bacteremia.
  • Patients were grouped based on initial vancomycin dosing (≥15 mg/kg q6h vs. other).
  • Area under the curve (AUC) was calculated using three pharmacokinetic methods; trapezoidal equation (Method A) was analyzed for correlation.

Main Results:

  • Fifty-five patients received vancomycin ≥15 mg/kg q6h, with 99 trough concentrations assessed.
  • The probability of achieving AUC/MIC > 400 varied widely (16.4%–90.9%) with a median trough of 11.4 mg/L in the higher dose group.
  • An AUC/MIC of 400 correlated to a trough concentration of 11 mg/L using the trapezoidal method.

Conclusions:

  • Vancomycin dosing of 15 mg/kg every 6 hours in children yields variable AUC/MIC > 400 achievement.
  • The AUC/MIC target of 400 in pediatric patients correlates to a trough concentration of 11 mg/L when using the trapezoidal method.
  • Pharmacokinetic method choice significantly impacts AUC/MIC calculations and target attainment assessment in pediatric vancomycin therapy.
Abstract

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
342
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
303
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
503
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
398
Estimation of k and VD of Aminoglycosides01:20

Estimation of k and VD of Aminoglycosides

Aminoglycosides are a class of antibiotics used to treat various bacterial infections. Clinicians must determine the elimination rate constant (k) and volume of distribution (VD) to optimize therapeutic efficacy and minimize toxicity. The k value represents the rate at which the drug is removed from the body, and the VD reflects the degree to which the drug distributes into body tissues. Accurately estimating these parameters allows healthcare professionals to tailor drug dosing to individual...
289
Pharmacodynamic Models: Overview01:27

Pharmacodynamic Models: Overview

Pharmacodynamic (PD) responses describe the interaction between a drug and its biological target, culminating in a physiological effect. These responses can be classified into different types: continuous variables, such as blood glucose levels; categorical outcomes, like survival rates; and time-to-event metrics, such as disease progression. Understanding and modeling PD responses are critical for optimizing drug efficacy and safety.PD models describe the relationship between drug concentration...
54